Evidence map›Paper›PMID 41632538›Full record

ArticleJCI insight2026

Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma.

Rimas V Lukas, Ruochen Du, Harrshavasan Congivaram, Kathleen McCortney, Karan Dixit, Craig Horbinski, Margaret Schwartz, Raymond Lezon, Lauren Singer, Ditte Primdahl and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rimas V LukasDepartment of Neurology, and.
Ruochen DuMalnati Brain Tumor Institute, Northwestern University, Chicago, Illinois, USA.
Harrshavasan CongivaramMalnati Brain Tumor Institute, Northwestern University, Chicago, Illinois, USA.
Kathleen McCortneyMalnati Brain Tumor Institute, Northwestern University, Chicago, Illinois, USA.
Karan DixitDepartment of Neurology, and.
Craig HorbinskiMalnati Brain Tumor Institute, Northwestern University, Chicago, Illinois, USA.
Margaret SchwartzDepartment of Neurology, and.
Raymond LezonDepartment of Neurology, and.
Lauren SingerDepartment of Neurology, and.
Ditte PrimdahlDepartment of Neurology, and.
Jigisha ThakkarDepartment of Neurology, Loyola University, Chicago, Illinois, USA.
Amy B HeimbergerMalnati Brain Tumor Institute, Northwestern University, Chicago, Illinois, USA.
Roger StuppDepartment of Neurology, and.
Priya KumthekarDepartment of Neurology, and.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An expanded access program of depatuxizumab mafodotin for patients with progressive glioblastoma explores the relationship between tumor EGFR expression and outcomes.

Indexed as

Antibodies, Monoclonal, HumanizedBiomarkers, TumorBrain NeoplasmsGlioblastomaErbB ReceptorsHumansAntibodies, Monoclonal, HumanizedBiomarkers, Tumordepatuxizumab mafodotinEGFR protein, humanErbB ReceptorsBrain cancerNeuroscienceOncology

Identifiers

PMID41632538
PMCPMC13043081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.